Janssen-Vanderbilt; Baxter-Northwestern R&D Pacts Support Idea of Academic Labs as CROs

J&J company Janssen Pharmaceutica signed a three-year, $10 million deal with Vanderbilt to develop new treatments for schizophrenia, while Baxter has signed a broad biomedical R&D pact with Northwestern that could be worth as much as $3 million.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.